How does retatrutide work?

Retatrutide is designed to activate three receptors at once — GIP, GLP-1, and glucagon. In simple terms, the GLP-1 and GIP activity is intended to reduce appetite and improve blood-sugar handling, while glucagon-receptor activity is thought to increase energy expenditure. This 'triple agonist' mechanism is the reason it's studied for weight loss. Note that this understanding comes from clinical research; retatrutide is investigational and not FDA-approved or available by prescription.

The three pathways, plainly

GLP-1: slows stomach emptying and signals fullness, so you eat less. This is the pathway semaglutide uses.

GIP: works alongside GLP-1 on appetite and metabolism. Tirzepatide adds this second pathway.

Glucagon: in this context, it's studied for its potential to raise energy expenditure — the piece unique to retatrutide's triple-agonist design.

How it compares to what's available now

Semaglutide (single pathway) and tirzepatide (dual pathway) are available today under physician supervision and have established dosing and safety monitoring. Retatrutide's third pathway is promising in trials but has not cleared regulatory review, so no approved dosing or supply exists.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/answers.